InsiderSignal.AI

InsiderSignal.ai

BEAM - Beam Therapeutics Inc.

Insider Sale by Ciaramella Giuseppe (Pres)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

1 week ago, Ciaramella Giuseppe, serving as Pres at Beam Therapeutics Inc. (BEAM), sold 11,810 shares at $24.58 per share, for a total transaction value of $290,290.00. Following this transaction, Ciaramella Giuseppe now holds 218,406 shares of BEAM.

This sale represents a 5.00% decrease in Ciaramella Giuseppe's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, April 1, 2026 and publicly disclosed via SEC Form 4 filing on Monday, April 6, 2026, 5 days after the trade was made.

Beam Therapeutics Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Ciaramella Giuseppe

Pres

Giuseppe Ciaramella, Ph.D. is the President and Chief Scientific Officer of Beam Therapeutics Inc., a role he has held since January 2020.[[1]](https://beamtx.com/executive_leadership/giuseppe-ciaramella-ph-d/)[[2]](https://www.marketscreener.com/insider/GIUSEPPE-CIARAMELLA-A2U7WQ/) With over 20 years of experience in drug discovery, he previously served as Chief Scientific Officer of the Infectious Diseases division at Moderna Therapeutics, where he contributed to the development of some of the first mRNA vaccines dosed in humans.[[1]](https://beamtx.com/executive_leadership/giuseppe-ciaramella-ph-d/)[[2]](https://www.marketscreener.com/insider/GIUSEPPE-CIARAMELLA-A2U7WQ/) Earlier, he was Vice President and Head of Collaborative Research at Boehringer Ingelheim, and held leadership positions at Pfizer for 14 years, including Head of Biotherapeutics, Antivirals, and Lead Discovery, contributing to clinical candidates and the anti-HIV drug Maraviroc (Selzentry™), which won the USA Prix Galien in 2008.[[1]](https://beamtx.com/executive_leadership/giuseppe-ciaramella-ph-d/)[[2]](https://www.marketscreener.com/insider/GIUSEPPE-CIARAMELLA-A2U7WQ/) Dr. Ciaramella holds a Ph.D. in Biochemistry and Molecular Biology from University College London and is a member of the Infectious Diseases Society of America (IDSA) and the American Society of Gene Therapy (ASGT).[[1]](https://beamtx.com/executive_leadership/giuseppe-ciaramella-ph-d/)[[2]](https://www.marketscreener.com/insider/GIUSEPPE-CIARAMELLA-A2U7WQ/) He recently sold 35,000 shares of Beam Therapeutics common stock on February 24, 2026.[[3]](https://www.tradingview.com/news/tradingview:00823653c317a:0-beam-therapeutics-president-sells-35-000-shares/)[[5]](https://longbridge.com/news/277095918) Additionally, he is a founder and CEO of Orbital Therapeutics, Inc., focused on RNA-based medicines.[[2]](https://www.marketscreener.com/insider/GIUSEPPE-CIARAMELLA-A2U7WQ/)

View full insider profile →

Trade Price

$24.58

Quantity

11,810

Total Value

$290,290.00

Shares Owned

218,406

Trade Date

Wednesday, April 1, 2026

8 days ago

SEC Filing Date

Monday, April 6, 2026

Filed 5 days after trade

HEALTHCAREBIOTECHNOLOGY

About Beam Therapeutics Inc.

Company Overview

No company information available
View news mentioning BEAM

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5421751

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime